Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Enhancement of radiation response of a murine mammary carcinoma by two nitrofuran derivatives

Journal Article · · Radiat. Res., v. 64, no. 3, pp. 443-451
DOI:https://doi.org/10.2307/3574234· OSTI ID:4102140

Two nitrofuran derivatives, NF-131 [1-(5-nitro-2-furyl)-3-piperidino-1- propanone semicarbazone hydrochloride], and nifuroxime (anti-5-nitro-2- furaldoxime), have been tested for their effect on the TCD50 of a C3H mouse mammary carcinoma and on murine jejunal epithelium. NF-131, at a dose of 2 mg/ mouse, caused a reduction in the TCD50 by a factor of 1.21 to 1.23 when administered iv 3, 10, or 30 min before irradiation. This drug dose had no effect on tumor growth and only a minimal effect on the radioresponse of jejunal epithelium, but caused death in about 3 percent of the mice. Nifuroxime, at a dose of 0.05 mg/g body weight, reduced the TCD50 by a factor of 1.36 when administered ip 10 min before irradiation, but was lethal for 22 percent of the mice. A dose of 0.10 mg/g enhanced the tumor radioresponse by a factor of 1.48 when administered 10 min before irradiation, but by lesser factors at 3 and 30 min. This dose was lethal to 37 percent of the mice. Both doses of nifuroxime inhibited tumor growth temporarily, but neither enhanced the radioresponse of jejunal epithelium. (auth)

Research Organization:
Univ. of Texas, Houston
NSA Number:
NSA-33-015079
OSTI ID:
4102140
Journal Information:
Radiat. Res., v. 64, no. 3, pp. 443-451, Journal Name: Radiat. Res., v. 64, no. 3, pp. 443-451; ISSN RAREA
Country of Publication:
United States
Language:
English